- $4.19m
- $3.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -714.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.09 | 0.13 | 0.04 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Directors
- Frederick Telling CHM (70)
- Michael Sullivan CEO (61)
- Alan Dunton IND (67)
- Robert Koski IND (62)
- Kimberly Murphy IND (59)
- Charles Pope IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 6th, 1996
- Public Since
- July 9th, 2003
- No. of Shareholders
- 40
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 21,475,289
- Address
- 1990 MAIN STREET, SUITE 750, SARASOTA, 34236
- Web
- https://www.oragenics.com/
- Phone
- +1 8132867900
- Contact
- Tirth Patel
- Auditors
- Cherry Bekaert LLP
Upcoming Events for OGEN
Q2 2025 Oragenics Inc Earnings Release
Similar to OGEN
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
Biomx
NYSE MKT
FAQ
What is the Oragenics share price?
As of Today at 22:29 UTC, shares in Oragenics are trading at $0.19. This share price information is delayed by 15 minutes.
How has the Oragenics share price performed this year?
Shares in Oragenics last closed at $0.19 and the price had moved by -81.44% over the past 365 days. In terms of relative price strength the Oragenics share price has underperformed the S&P500 Index by -83.26% over the past year.
What are the analyst and broker recommendations for Oragenics?
The overall consensus recommendation for Oragenics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oragenics dividend yield?
Oragenics does not currently pay a dividend.
Does Oragenics pay a dividend?
Oragenics does not currently pay a dividend.
When does Oragenics next pay dividends?
Oragenics does not currently pay a dividend.
How do I buy Oragenics shares?
To buy shares in Oragenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oragenics?
As of the previous close price of $0.19, shares in Oragenics had a market capitalisation of $4.19m.
Where are Oragenics shares listed?
Here are the trading details for Oragenics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: OGEN
What kind of share is Oragenics?
Based on an overall assessment of its quality, value and momentum Oragenics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oragenics share price forecast for 2025?
The analyst consensus target price for shares in Oragenics is $1.00. That is 413.08% above the last closing price of $0.19.
Analysts covering Oragenics currently have a consensus Earnings Per Share (EPS) forecast of -$0.37 for the next financial year.
Find out moreWhat is the trend in the Oragenics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oragenics. Over the past six months, its share price has underperformed the S&P500 Index by -34.05%.
As of the last closing price of $0.19, shares in Oragenics were trading -57.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oragenics PE Ratio?
The Oragenics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oragenics?
Oragenics' management team is headed by:
- Frederick Telling - CHM
- Michael Sullivan - CEO
- Alan Dunton - IND
- Robert Koski - IND
- Kimberly Murphy - IND
- Charles Pope - IND